

# Venous Thromboembolism Global Market Segmentation and Major Players Analysis 2022

*PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025*

PUNE, INDIA, January 6, 2017  
/EINPresswire.com/ -- GET SAMPLE REPORT @  
<https://www.wiseguyreports.com/sample-request/717370-pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2025>

Pharma Point: [Venous Thromboembolism](#) - Global Drug Forecast and Market Analysis to 2025



**WISE GUY**  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ [sales@wiseguyreports.com](mailto:sales@wiseguyreports.com)

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

## Summary

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT). The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual's deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs. Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).

## Highlights

- The NOACs will see a significant increase in patient shares for the treatment of VTE and VTE primary prophylaxis against the established vitamin K antagonists and heparins. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the VTE market?
- The current late-stage VTE pipeline consists of betrixaban, in particular, which is vying for entry into the VTE market as the first NOAC approved for extended prophylaxis in acute medically ill patients- a significant unmet need in VTE space. Xarelto is also contending for entry in this space through an additional label expansion for the established therapy. Will the late-stage drugs make a significant impact on the VTE market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a significant increase in the VTE population, in terms of diagnosed incidence and

recurrent attacks, as well as an increase in the prophylaxis population. How will epidemiological changes impact the growth of the future market?

### Scope

- Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

### Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global VTE therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

### Table of Contents

1 Table of Contents	9
1.1 List of Tables	14
1.2 List of Figures	19
2 Introduction	21
2.1 Catalyst	21
2.2 Related Reports	22
2.3 Upcoming Related Reports	22
3 Disease Overview	23
3.1 Etiology and Pathophysiology	23
3.1.1 Etiology	23
3.1.2 Pathophysiology	24
3.2 Symptoms	25
3.3 Prognosis	26
3.4 Quality of Life	27
4 Epidemiology	29
4.1 Disease Background	29
4.2 Risk Factors and Comorbidities	30
4.3 Global Trends	31

4.4 Forecast Methodology	33
4.4.1 Sources Used	33
4.4.2 Forecast Assumptions and Methods	38
4.4.3 Sources Not Used	54
4.5 Epidemiological Forecast for VTE, 2015-2025	55
4.5.1 Pulmonary Embolism	55
4.5.2 Deep Vein Thrombosis	58
4.5.3 VTE	61
4.5.4 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE	71
4.5.5 Number of Primary Total Knee Replacements and Revisions	72
4.5.6 Number of Total Hip Replacements	74
4.6 Discussion	76
4.6.1 Epidemiological Forecast Insight	76
4.6.2 Limitations of the Analysis	77
4.6.3 Strengths of the Analysis	78
5 Disease Management	79
5.1 Diagnosis and Treatment Overview	79
5.1.1 Diagnosis	79
5.1.2 Treatment Guidelines and Leading Prescribed Drugs	79
5.1.3 Clinical Practice	83
6 Competitive Assessment	101
6.1 Overview	101
6.2 Product Profiles - Oral Anticoagulants	104
6.2.1 Warfarin (Widely Genericized)	10
7 Unmet Needs and Opportunities	139
7.1 Overview	139
7.2 Unmet Needs and Opportunities	140
7.2.1 Inadequate Prophylaxis in Acute Medically Ill Patients	140
7.2.2 Complicated Dose Adjustments with New Oral Anticoagulants	142
8 Pipeline Assessment	160
8.1 Overview	160
8.2 Clinical Trial Mapping	160
8.2.1 Clinical Trials by Country	160
8.2.2 Clinical Trials by Phase and Trial Status	161
8.3 Promising Drugs in Clinical Development	162
9 Current and Future Players	176
9.1 Overview	176
9.2 Trends in Corporate Strategy	178
9.3 Company Profiles	179
10 Market Outlook	195
10.1 Global Markets	195
10.1.1 Forecast	195
10.1.2 Drivers and Barriers - Global Issues	200
10.2 US	203
...Continued	
ACCESS REPORT @ <a href="https://www.wiseguyreports.com/reports/717370-pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2025">https://www.wiseguyreports.com/reports/717370-pharmapoint-venous-thromboembolism-global-drug-forecast-and-market-analysis-to-2025</a>	

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](https://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.